Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study.
Zhi-Chao JiangYongkun SunWen ZhangChengxu CuiLin YangAiping ZhouPublished in: Asia-Pacific journal of clinical oncology (2020)
SOX has similar survival benefits to XELOX and is well-tolerated in Chinese patients with GC following D2 gastrectomy.